Abstract:Mutations in activin-like kinase 2 (ALK2), e.g., ALK2-R206H, induce aberrant signaling to SMAD1/5/8, leading to Fibrodysplasia Ossificans Progressiva (FOP). In spite of extensive studies, the underlying mechanism is still unclear. Here, we quantified the homomeric and heteromeric interactions of ACVR2A, ACVR2B, ALK2-WT, and ALK2-R206H by combining IgG-mediated immobilization of one receptor with fluorescence recovery after photobleaching (FRAP) measurements on the lateral diffusion of a co-expressed receptor. ACVR2B formed stable homomeric complexes that were enhanced by Activin A (ActA), while ACVR2A required ActA for homodimerization. ALK2-WT, but not ALK2-R206H, exhibited homomeric complexes unaffected by ActA. ACVR2B formed ActA-enhanced heterocomplexes with ALK2-R206H or ALK2-WT, while ACVR2A interacted mainly with ALK2-WT. The extent of the homomeric complex formation of ACVR2A or ACVR2B was reflected in their ability to induce the oligomerization of ALK2-R206H and ALK2-WT. Thus, ACVR2B, which forms dimers without ligand, induced ActA-independent ALK2-R206H clustering but required ActA for enhancing the oligomerization of the largely dimeric ALK2-WT. In contrast, ACVR2A, which undergoes homodimerization in response to ActA, required ActA to induce ALK2-R206H oligomerization. To investigate whether these interactions are translated into signaling, we studied signaling by the FOP-inducing hyperactive ALK2-R206H mutant, with ALK2-WT signaling as control. The activation of SMAD1/5/8 signaling in cells expressing ALK2-R206H alone or together with ACVR2A or ACVR2B was measured by blotting for pSMAD1/5/8 and by transcriptional activation assays using BRE-Luc reporter. In line with the biophysical studies, ACVR2B activated ALK2-R206H without ligand, while activation by ACVR2A was weaker and required ActA. We propose that the homodimerization of ACVR2B or ACVR2A dictates their ability to recruit ALK2-R206H into higher complexes, enabling the homomeric interactions of ALK2-R206H receptors and, subsequently, their activation.

Functional Antagonism Between Activin And Osteogenic Protein-1 In Human Embryonal Carcinoma Cells

Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects.

Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B

Insight into Molecular Mechanism for Activin A-Induced Bone Morphogenetic Protein Signaling

Inhibin α-subunit N terminus interacts with activin type IB receptor to disrupt activin signaling

Intracellular signaling of osteogenic protein-1 through Smad5 activation.

Regulation of Cell Proliferation, Apoptosis, and Carcinogenesis by Activin

Activin A induces a non-fibrotic phenotype in smooth muscle cells in contrast to TGF-β

Identification of Type I Receptors for Osteogenic Protein-1 and Bone Morphogenetic Protein-4.

How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva

Engagement of Activin and Bone Morphogenetic Protein Signaling Pathway Smad Proteins in the Induction of Inhibin B Production in Ovarian Granulosa Cells.

Osteopontin Regulates the Proliferation of Rat Aortic Smooth Muscle Cells in Response to Gingipains Treatment

Effects of Activin A on IL--1#beta# Secretion by the Murine Macrophages

Two Activin Type 2B Receptors from Sea Bream Function Similarly in vitro

Activin receptor type 2A (ACVR2A) functions directly in osteoblasts as a negative regulator of bone mass

Follistatins neutralize activin bioactivity by inhibition of activin binding to its type II receptors

Repression of Bone Morphogenetic Protein and Activin-inducible Transcription by Evi-1

Follistatin Forms a Stable Complex With Inhibin A That Does Not Interfere With Activin A Antagonism

Activin A-induced Increase in LOX Activity in Human Granulosa-Lutein Cells is Mediated by CTGF.

The Activation of the Fibrodysplasia Ossificans Progressiva-Inducing ALK2-R206H Mutant Depends on the Distinct Homo-Oligomerization Patterns of ACVR2B and ACVR2A

Activin A promotes the development of acquired heterotopic ossification and is an effective target for disease attenuation in mice